Selected article for: "LCMV infection and VV infection"

Author: Kim, Sung-Kwon; Cornberg, Markus; Wang, Xiaoting Z.; Chen, Hong D.; Selin, Liisa K.; Welsh, Raymond M.
Title: Private specificities of CD8 T cell responses control patterns of heterologous immunity
  • Document date: 2005_2_21
  • ID: 55gi6gyx_30
    Snippet: To systematically address this issue, we examined the fate of A11R 198-specific CD8 T cells before and after heterologous virus infection using a PBL longitudinal analysis, as in Fig. 1. Fig. 4 B shows that low levels (0.2-0.5%) of A11R 198-specific CD8 T cells were present in LCMV-immune PBLs. However, upon VV infection (day 12), only some of the LCMV-immune mice (mouse nos. 4, 7, 10, 12, 13, and 19) showed significant expansions of T cells spec.....
    Document: To systematically address this issue, we examined the fate of A11R 198-specific CD8 T cells before and after heterologous virus infection using a PBL longitudinal analysis, as in Fig. 1. Fig. 4 B shows that low levels (0.2-0.5%) of A11R 198-specific CD8 T cells were present in LCMV-immune PBLs. However, upon VV infection (day 12), only some of the LCMV-immune mice (mouse nos. 4, 7, 10, 12, 13, and 19) showed significant expansions of T cells specific to the cross-reactive VV epitope, whereas others did not (mouse nos. 1, 2, 3, and 10 others not depicted; Fig. 4 B) . Altogether, longitudinal analysis experiments revealed that 6 out of 19 LCMV-immune mice challenged with VV made relatively strong (Ͼ1.5% of CD8 T cells) responses to the A11R 198 peptide. In these experiments, four of the A11R 298 responders (mouse nos. 4, 7, 10, and 13) also responded to the GP33/34 epitope, three (mouse nos. 10, 12, and 19) responded to the NP205 epitope, and one (mouse no. 12) responded to the GP118 epitope (unpublished data).

    Search related documents:
    Co phrase search for related documents
    • cross reactive VV epitope and lcmv immune mouse: 1, 2
    • cross reactive VV epitope and VV epitope: 1, 2, 3, 4, 5
    • issue address and longitudinal analysis: 1
    • issue address and low level: 1, 2
    • issue address and virus infection: 1, 2, 3, 4, 5, 6
    • lcmv immune mouse and longitudinal analysis: 1
    • lcmv immune mouse and VV challenge: 1
    • lcmv immune mouse and VV epitope: 1, 2, 3, 4
    • longitudinal analysis and low level: 1
    • longitudinal analysis and significant expansion: 1
    • longitudinal analysis and virus infection: 1
    • low level and virus infection: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25
    • significant expansion and virus infection: 1